… The success of atezolizumab plus bevacizumab treatment contributed to a shift in systemic
therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer …

… -term outcome of patients with advanced hepatocellular carcinoma. Because of the high
prevalence of liver cirrhosis in hepatocellular carcinoma patients, these approaches must be …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide.
Despite tremendous efforts to diagnose and institute new treatment regimens, the prognosis is …

Although hepatocellular carcinoma (HCC) is one of the deadliest health burdens worldwide,
few drugs are available for its clinical treatment. However, in recent years, major …

… Here, we show that MPHOSPH1 is overexpressed in hepatocellular carcinoma (HCC)
cells, where it is essential for proliferation. Attenuating MPHOSPH1 expression with a tumor-…

… discuss promising therapeutic target, with focus on those targets with available drugs under
development, for treatment of HCC. We also aim to highlight potential predictive biomarkers …

… of CSCs, which may be potential therapeutic targets. The role of … therapeutic targets for
CSCs. Conventional cytotoxic drugs kill differentiated cancer cells and cause a reduction in tumor …

… HCC markers and therapeutic targets. Keywords: Hepatocellular carcinoma, Biochemical …
observations, miR-372 has been suggested as a potential therapeutic target for HCC[74]. …

… to improve tumor characterization to optimize personalized treatment for patients with
hepatocellular carcinoma (HCC). Exome sequencing analysis of 243 liver tumors identified …

… , but not androgens, as a potential new and better therapeutic target for the battle of HCC. …
the development of hepatocellular carcinoma (HCC), the etiology of this liver cancer remains …